WAC

WW domain containing adaptor with coiled-coil

Explore in graph →CI-GENE-00038677HGNC:17327 ENSG00000095787 NCBI 51322 Approved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
WAC Fusion1
Futibatinib	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	1	submitted	EID11643 In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC) PMID 34551969 · Meric-Bernstam et al., 2022 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (4)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved4 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Diffuse Large B-Cell Lymphoma (Duke, Cell 2017) dlbcl_duke_2017	Diffuse Large B-Cell Lymphoma Unclassifiable	Ssm

Literature

Linked publications (0)

Data not yet available

No publication linked to this gene yet.